USE IR-SPECTROSCOPY IN TREATMENT ONCOLOGICAL PATIENTS WITH BONE METASTASES BY 153Sm-OXABIFOR-Reference-Cited by-同舟云学术

USE IR-SPECTROSCOPY IN TREATMENT ONCOLOGICAL PATIENTS WITH BONE METASTASES BY 153Sm-OXABIFOR

Published:2020-09-21 Issue: Volume: Page:46-51
ISSN:
Container-title:Problems of Atomic Science and Technology
language:
Short-container-title:

Author:

Dikiy N. P.,Krasnoselsky N. V.,Bereznyak E. P.,Grushka A. V.,Medvedeva E. P.

Abstract

Using infrared spectroscopy, we studied the character of intermolecular interactions in the samples blood plasma of oncological patients with bone metastases in the treatment of their modern β-emitter 153Sm-oxabifor. The therapeutic dose of the 153Sm-oxabifor was 1.0 mCi/kg of the patient's body weight. Analysis of the IR-spectra showed that already after the first course of palliative radionuclide therapy there is a tendency to balance the products of free radical nature and antioxidants, which indicates the effectiveness of the treatment. Molecular changes in the blood plasma of cancer patients with bone metastases registered using infrared spectroscopy are specifc during palliative therapy.

Publisher

Problems of Atomic Science and Technology

Reference22 articles.

1. A.N.Serafini. Therapy of metastatic bone pain // J. Nucl. Med. 2001, v.42(6), p.895-906.

2. N.Randit-Taskar, M.Batraki, C.R.Divgi. Radiopharmaceutical therapy for pflftion of bone pain from osseous metastases // J. Nucl. Med. 2004, v.45(8), p.1358-1365.

3. O.I.Solodyannikova, V.V.Danilenko, et al. Samarium-153 oxabifor in the complex therapy of metastatic bone lesion // Ukrainian journal of radiology. 2014, vol.XXII, p.109-117.

4. V.Lewingtone. Cancer therapy using boneseeking isotopes // Phys. Med. Biol. 1996, v.4, p.2027-2042.

5. C.Hindorf, G.Glatting, C.Chiesa, et al. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry // Eur. J. Nucl. Med. Mol. Imaging. 2010, v.37, N.6, p.1238-1250.